Microarray patches for transdermal drug delivery: a critical narrative review of technological innovations, CMC challenges, clinical translation, and global health implementation
6 affiliations
- 1Ami Polymer Pvt. Ltd., Khanvel, India
- 2Infectious Disease Epidemiology Research Group, Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
- 3Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia
- 4School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) Deemed to be University, Bhubaneswar, India
- 5Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia
- 6Department of Chemistry, Government College of Engineering, Keonjhar, India
Abstract
Microarray patches (MAPs), alternatively known as microneedle patches, is a paradigm shift in the administration of pharmaceutical agents and vaccines. By utilising micron-scale projections to breach the stratum corneum, MAPs bridge the gap between the convenience of transdermal patches and the efficacy of hypodermic injections. This critical narrative review synthesises advances in MAP technology for transdermal drug delivery, focusing on technological innovations, chemistry, manufacturing, and control (CMC) challenges, clinical translation, regulatory considerations, and global health implementation. Special emphasis is placed on CMC challenges, including sterilisation and stability profiling, as well as the landscape of Clinical Trials, highlighting recent frameworks for pivotal Phase III studies in measles and rubella. We conclude by evaluating the programmatic suitability of MAPs for low- and middle-income countries (LMICs), addressing critical barriers such as cold-chain logistics and trypanophobia. A coordinated evolution from product-by-product model to platform-industrialisation model involving vaccine, polymer and device producing companies, regulators, global-health agencies including World health organization (WHO), and technology enablers is necessary. The Measles-Rubella programme provides an important template. MAPs’ value is not about replacing a syringe but enabling equitable distribution of vaccination; a strategy to make vaccination less dependent on infrastructure. As scientific innovations, upscaling, unified regulatory frameworks and equitable access advance, MAPs will achieve global relevance.
Related
- Next-generation microneedle platforms for transdermal therapeutics: a comprehensive review of innovations and challenges
- Cardiac rehabilitation: from historical milestones to technological integration and global implementation
- Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation
- Artificial Intelligence-Driven Dietary Assessment Software: A Structured Narrative Review of Technological Advances, Persistent Measurement Error and Barriers to Clinical Translation
- Clinical translation of circulating tumor DNA: technological innovation and future pathways from molecular monitoring to precision decision-making
BibTeX
@article{pattnaik2026microarray,
title = {{Microarray patches for transdermal drug delivery: a critical narrative review of technological innovations, CMC challenges, clinical translation, and global health implementation}},
author = {Priyabrata Pattnaik and Lawrence Sena Tuglo and Mohammed Alissa and Snehasish Mishra and Abdullah Alghamdi and Mohammed A. Alshehri and Tawfiq N. Juraybi and Helal G. Alanazi and Ghada M. Alnafesah and Ranjan K. Mohapatra},
journal = {Journal of Pharmacy \& Pharmaceutical Sciences},
year = {2026},
month = nov,
doi = {10.3389/jpps.2026.17200},
url = {https://doi.org/10.3389/jpps.2026.17200},
note = {CC BY},
}
RIS
TY - JOUR
TI - Microarray patches for transdermal drug delivery: a critical narrative review of technological innovations, CMC challenges, clinical translation, and global health implementation
AU - Priyabrata Pattnaik
AU - Lawrence Sena Tuglo
AU - Mohammed Alissa
AU - Snehasish Mishra
AU - Abdullah Alghamdi
AU - Mohammed A. Alshehri
AU - Tawfiq N. Juraybi
AU - Helal G. Alanazi
AU - Ghada M. Alnafesah
AU - Ranjan K. Mohapatra
PY - 2026
DA - 2026/11/09
JO - Journal of Pharmacy & Pharmaceutical Sciences
DO - 10.3389/jpps.2026.17200
UR - https://doi.org/10.3389/jpps.2026.17200
AB - Microarray patches (MAPs), alternatively known as microneedle patches, is a paradigm shift in the administration of pharmaceutical agents and vaccines. By utilising micron-scale projections to breach the stratum corneum, MAPs bridge the gap between the convenience of transdermal patches and the efficacy of hypodermic injections. This critical narrative review synthesises advances in MAP technology for transdermal drug delivery, focusing on technological innovations, chemistry, manufacturing, and control (CMC) challenges, clinical translation, regulatory considerations, and global health implementation. Special emphasis is placed on CMC challenges, including sterilisation and stability profiling, as well as the landscape of Clinical Trials, highlighting recent frameworks for pivotal Phase III studies in measles and rubella. We conclude by evaluating the programmatic suitability of MAPs for low- and middle-income countries (LMICs), addressing critical barriers such as cold-chain logistics and trypanophobia. A coordinated evolution from product-by-product model to platform-industrialisation model involving vaccine, polymer and device producing companies, regulators, global-health agencies including World health organization (WHO), and technology enablers is necessary. The Measles-Rubella programme provides an important template. MAPs’ value is not about replacing a syringe but enabling equitable distribution of vaccination; a strategy to make vaccination less dependent on infrastructure. As scientific innovations, upscaling, unified regulatory frameworks and equitable access advance, MAPs will achieve global relevance.
SN - 1482-1826
ER -